LifeStance Health Group, Inc. (NASDAQ:LFST – Get Rating) – Research analysts at William Blair lowered their Q1 2023 earnings per share (EPS) estimates for LifeStance Health Group in a note issued to investors on Wednesday, February 1st. William Blair analyst R. Daniels now expects that the company will post earnings per share of ($0.13) for the quarter, down from their prior forecast of ($0.12). The consensus estimate for LifeStance Health Group's current full-year earnings is ($0.60) per share. William Blair also issued estimates for LifeStance Health Group's Q2 2023 earnings at ($0.12) EPS, Q3 2023 earnings at ($0.11) EPS, Q4 2023 earnings at ($0.10) EPS and FY2023 earnings at ($0.47) EPS.
Get LifeStance Health Group alerts:LifeStance Health Group (NASDAQ:LFST – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. LifeStance Health Group had a negative return on equity of 18.01% and a negative net margin of 33.77%. The company had revenue of $217.56 million during the quarter, compared to the consensus estimate of $219.69 million.
Other equities research analysts also recently issued reports about the company. Morgan Stanley upgraded LifeStance Health Group from an "equal weight" rating to an "overweight" rating and set a $8.00 target price for the company in a report on Friday, January 6th. The Goldman Sachs Group lowered their target price on LifeStance Health Group from $9.00 to $8.00 and set a "neutral" rating for the company in a report on Tuesday, November 15th. Cowen lowered their target price on LifeStance Health Group from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Monday, November 14th. Jefferies Financial Group reiterated a "buy" rating and issued a $7.25 target price on shares of LifeStance Health Group in a report on Monday, November 7th. Finally, Cowen lowered their target price on LifeStance Health Group from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Monday, November 14th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $8.21.LifeStance Health Group Price Performance
Shares of LFST opened at $5.53 on Monday. LifeStance Health Group has a 1 year low of $4.22 and a 1 year high of $11.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.25 and a quick ratio of 2.25. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of -6.91 and a beta of 0.61. The business has a 50-day moving average of $5.09 and a 200-day moving average of $6.37.
Institutional Investors Weigh In On LifeStance Health Group
Hedge funds and other institutional investors have recently modified their holdings of the company. OLD National Bancorp IN bought a new stake in shares of LifeStance Health Group during the fourth quarter valued at approximately $49,000. Dynamic Advisor Solutions LLC bought a new stake in shares of LifeStance Health Group during the fourth quarter valued at approximately $56,000. Ameritas Investment Partners Inc. increased its holdings in shares of LifeStance Health Group by 56.6% during the first quarter. Ameritas Investment Partners Inc. now owns 5,575 shares of the company's stock valued at $56,000 after acquiring an additional 2,016 shares in the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of LifeStance Health Group during the second quarter valued at approximately $63,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in shares of LifeStance Health Group during the third quarter valued at approximately $75,000. Institutional investors own 76.49% of the company's stock.
LifeStance Health Group Company Profile
(Get Rating)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Read More
- Get a free copy of the StockNews.com research report on LifeStance Health Group (LFST)
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.